Key malaria vaccine set for field trial
The Times of India
April 23, 2019
April 23, 2019
LILONGWE:
Malawi will on Tuesday spearhead large scale pilot tests for the world’s most
advanced experimental malaria vaccine in a bid to prevent the disease that
kills hundreds of thousands across Africa each year.
After
over three decades in development and almost $1 billion in investment, the
cutting-edge trial will be rolled out in Malawi’s capital Lilongwe this week
and then in Kenya and Ghana next week.
It
aims to immunise 1,20,000 children aged two years and under to assess the
effectiveness of the pilot vaccine and whether the delivery process is
feasible. Four successive doses must be administered on a strict timetable for
it to work.
Trade-named
Mosquirix, the drug has been developed by British pharmaceutical giant
GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative.
It
passed previous scientific testing — including five years of clinical trials on
15,000 people in seven countries — and was approved for the pilot programme in
2015.
Malaria
episodes reduced by 40% in the trials.
Although
the potential vaccine will not give full protection against the mosquito-borne
disease, it is the furthest along in development and so far the most effective.
Scientists
say if it was rolled out on a large scale it could save hundreds of thousands
of lives.
The
World Health Organisation (WHO) believes that the new vaccine brings a key new
tool beyond mosquito nets, insecticides and drugs in the battle against the
disease.
Malaria
killed 435,000 people in 2017. The majority of them were children under five in
Africa. “Malaria can kill a child in less than 24 hours,” said researcher
Tisungane Mvalo, a paediatrician at University of North Carolina at Chapel Hill
Project-Malawi in Lilongwe.
“And even if the child survives, malaria can
impact every organ, causing brain injury or kidney issues. Prevention is better
than treatment.”
WHO’s
latest report on malaria showed that the number of cases climbed to 219 million
in 2017, two million higher than 2016.
“Despite gains over the last decade, we have
seen a stagnation in malaria control efforts in recent years,” said researcher
Jonathan Juliano from the University of North Carolina. “In certain areas of
Africa, we have actually seen rates of malaria infection get worse.”
The
fight against malaria has also been complicated by mosquitoes building up
resistance to some commonly used insecticides, according to WHO.
Malawi,
Ghana and Kenya were selected for the trial because malaria rates are high and
they have a long history of use of bed nets and other interventions. The
large scale pilot is the latest step in decades of work seeking to eradicate
malaria. Despite concerns over recent rises in malaria cases, the numbers dying
from the disease has fallen nearly two-thirds since the turn of the century
Reference:
Comments
Post a Comment